Results 181 to 190 of about 4,268 (199)

Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial

HIV Clinical Trials, 2018
Kenneth Hugh Mayer, Robert Grant, Ian Frank   +2 more
exaly  

Cabotegravir/emtricitabine/tenofovir-disoproxil-fumarate

Reactions Weekly, 2023
openaire   +1 more source

Review of Synthetic Routes and Final Forms of Integrase Inhibitors Dolutegravir, Cabotegravir, and Bictegravir

Organic Process Research and Development, 2019
David Hughes
exaly  

COMBINATION OF CABOTEGRAVIR AND LEVONORGESTREL

2022
AKHAVEIN NIMA, ALIDORI SIMONE, VELTHUISEN EMILE JOHANN   +2 more
openaire   +3 more sources

Early virological failure with cabotegravir/rilpivirine

Journal of Antimicrobial Chemotherapy
L Bailón, S Sábato, J Coll, J R Santos, C Miranda, T Puig, A D´Avolio, R Paredes, J Moltó, E Negredo   +9 more
openaire   +3 more sources

Cabotegravir: The first long-acting injectable for HIV pre-exposure prophylaxis.

American Journal of Health-System Pharmacy, 2022
exaly  

CRYSTALLINE FORM OF CABOTEGRAVIR SODIUM

2018
ADAMER VERENA, THALER ANDREA
openaire   +5 more sources

METHOD FOR TREATING HIV WITH CABOTEGRAVIR AND RILPIVIRINE

2021
CRAUWELS HERTA MARIA LUDOVICA, FORD SUSAN L, MARGOLIS DAVID ANDREW, ROSSENU STEFAAN LOUIS F, SPREEN WILLIAM ROBERT, VAN SOLINGEN-RISTEA RODICA MIHAELA, WILLIAMS PETER EVAN OWEN   +6 more
openaire   +2 more sources

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

Lancet, The, 2017
Daniel Podzamczer, Sandy Griffith, Juan González-García   +2 more
exaly  

Cabotegravir/Rilpivirine/Testosterone

Reactions Weekly
openaire   +1 more source